XL t(4;14) FGFR3/IGH DF

Translocation/Dual Fusion Probe

Order Number
D-5108-100-OG
Package Size
100 µl (10 Tests)
Labels
  
Chromosomes
414
Regulatory Status
IVDD

IVDR Certification

This probe is IVDR-certified in compliance with the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR).

MetaSystems Probes has already certified a large part of its portfolio, according to IVDR. For organizational reasons, we currently provide only the IVDD product.

Please use the switch to change to the IVDR product.

IVDDIVDRDiscover all IVDR-certified products

Product Description

XL t(4;14) FGFR3/IGH DF

XL t(4;14) FGFR3/IGH DF consists of an orange-labeled probe hybridizing to the FGFR3 gene region at 4p16.3 and a green-labeled probe hybridizing to the IGH gene region at 14q32.3.

Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.

Need assistance or a quote?

Clinical Details

The most frequent primary abnormalities in multiple myeloma (MM) are trisomies of odd-numbered chromosomes or translocations involving the immunglobulin heavy chain (IGH) gene locus. The most common MM-associated IGH translocations are t(11;14), t(4;14), t(6;14), t(14;16) and t(14;20) in the order of their occurrence. The consequence of these rearrangements is the dysregulation of genes juxtaposed to transcriptional enhancers in the IGH locus. Prognosis and risk stratification strongly depend on the detection and interpretation of cytogenetic primary abnormalities. t(14;16) and t(14;20) are considered as high risk, t(4;14) as intermediate risk and t(6;14) and t(11;14) as standard risk cytogenetic aberrations in patients with MM based on FISH testing. Secondary aberrations are also influencing the outcome.
The recurrent translocation t(4;14)(p16;q32) is juxtaposing FGFR3 with the 3′ alpha IgH enhancer on der(14), whereas expression of NSD2 is controlled by the Eμ enhancer on der(4). FGFR3 overexpression is detectable in about 70% of t(4;14) positive MM patients, suggesting that FGFR3 dysregulation is not the crucial oncogenic event. The poor outcome of patients lacking FGFR3 expression due to the loss of der(14) is supporting this conclusion. Transcripts from the NSD2 locus on the other hand are found to be overexpressed in all t(4;14) positive MM cases, suggesting that this gene region plays a major role in the manifestation of MM.

Clinical Applications

  • Multiple Myeloma and Plasma Cell Neoplasms (MM)
Need assistance or a quote?

Images

XL t(4;14) FGFR3/IGH DF

XL t(4;14) IGH/FGFR3 DF hybridized to lymphocytes. Two normal interphases are shown.

Need assistance or a quote?

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
One green (1G), one orange (1O), and two greenorange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the respective loci.

Need assistance or a quote?

Literature

  • Chesi et al (1998) Blood 92:3025-3034
  • Keats et al (2003) Blood 15:4060-4069
  • Rajan and Rajkumar (2015) Blood Cancer J 5:e365

Downloads

News

IVDR Certification

MetaSystems Probes has received IVDR certification for our initial 26 fluorescence in situ hybridization (FISH) probes from the notified body, BSI. Achieving this milestone was not without its challenges, and we are delighted to have accomplished IVDR certification for this probe set at an early stage.

IVDR Certification

New Probes Catalog is Online!

 

MetaSystems Probes is pleased to announce the new catalog including new and innovative products and supporting information. A PDF version of the new catalog is available for download here.

New Probes Catalog is Online!